Search

Search Constraints

You searched for: Author/Creator Drilon, Alexander

Search Results

1. A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors. (21st July 2021)

2. A Phase I, First‐in‐Human Study of GSK2849330, an Anti‐HER3 Monoclonal Antibody, in HER3‐Expressing Solid Tumors. (21st July 2021)

3. A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. (28th November 2018)

4. Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. (March 2019)

5. ALK Inhibitors in Patients With ALK Fusion–Positive GI Cancers: An International Data Set and a Molecular Case Series. (27th April 2022)

6. Beyond the dose‐limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program. Issue 8 (24th February 2016)

7. BIOM-01. GENOMIC ALTERATIONS IN ALK FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH BRAIN METASTASES. (14th November 2022)

8. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Issue 12 (December 2016)

9. Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Alectinib. (April 2023)

10. Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment. (25th February 2022)